Treatment Considerations for Patients with High-Risk NDMM

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

During the 2024 IMS conference, teams from Cleveland, Ohio, and New York, New York, met to debate the latest advances in multiple myeloma.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.